FY2025 · ended Dec 31, 2025 · Revenue $9.89B, +2.2% YoY · Filed Feb 6, 2026
Biogen Inc. (BIIB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.9 billion and net income of $1.3 billion. Free cash flow was $2.1 billion. As of Sep 30, 2026 it held $1.3 billion in cash and investments and $7.4 billion in total debt.
Revenue (TTM)
$10.30B
+2.3% vs year-ago TTM
Net income (TTM)
$347.50M
-78.4% vs year-ago TTM
Operating cash flow (TTM)
$2.25B
-8.4% vs year-ago TTM
Free cash flow (TTM)
$2.07B
-10.1% vs year-ago TTM
EPS (TTM)
$2.34
-78.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
146.76M
+0.3% vs prior year
Net cash
$-6.10B
as of Sep 30, 2026
Operating margin
25.9%
FY 2021
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BIIB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875045
- Former names
- BIOGEN IDEC INC. (until Mar 20, 2015); BIOGEN IDEC INC (until Apr 25, 2007); IDEC PHARMACEUTICALS CORP / DE (until Nov 12, 2003); IDEC PHARMACEUTICALS CORP / CA (until Feb 14, 1997)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.9B | $9.7B | $9.8B | $10.2B | $11.0B |
| Operating income | — | — | — | — | $2.8B |
| Net income | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B |
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
| Operating cash flow | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B |
| Free cash flow | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B |
| Total assets | $29.4B | $28.0B | $26.8B | $24.6B | $23.9B |
| Total liabilities | $11.2B | $11.3B | $12.0B | $11.2B | $12.9B |
| Stockholders' equity | $18.3B | $16.7B | $14.8B | $13.4B | $11.0B |
| Cash and investments | $4.2B | $2.4B | $1.0B | $5.6B | $4.7B |
| Total debt | $6.7B | $6.7B | $7.4B | $6.7B | $6.7B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 1, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
All 1001 Biogen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.